ArticleDigital health
Quality, functionality, and features of a newly developed smartphone app for diabetes: A comparative analysis using Mobile app rating scale.
Article in Digital health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Therapeutic Trends in Diabetes Management: A Review on Oral Hypoglycemic Agents (OHAs) Utilization in Tertiary Care.Cardiovascular & hematological disorders drug targets · 2026Review
- Patients' perspectives on mobile health applications for diabetes self-management: A qualitative study in Malaysia.Digital healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Diabetes management requires continuous monitoring of glucose, medication, diet, and activity. With over 537 million cases globally, digital health solutions support self-care. This study assesses the Madhumeh Setu app, comparing its functionality, quality, and user experience with top diabetes apps using Mobile App Rating Scale (MARS). Study design: A four-phase evaluation was conducted: systematic app search from Google Play Store; assessment of essential app features based on AADE-7 guidelines; qualitative ratings by healthcare professionals using MARS, and user comparison of Madhumeh Setu with MySugr and BeatO through MARS. Results: Out of 2116 screened apps, 11 met the inclusion criteria. MySugr received the highest MARS rating (4.40 ± 0.14), followed by BeatO (4.12 ± 0.04) and Madhumeh Setu (4.05 ± 0.05). While MySugr scored highest overall, Madhumeh Setu performed similarly to BeatO in functionality and engagement. A one-way ANOVA showed that Madhumeh Setu differed significantly from MySugr ( Conclusions: This study underscores the potential of digital health solutions in diabetes care. As mobile health advances, culturally specific apps such as Madhumeh Setu will become vital for diabetes management. Future studies should use long-term trials to evaluate their effects on blood sugar, medication use, and well-being, with ongoing improvements based on user input to aid wider adoption, especially in low-and-middle-income countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.